The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA Peptide Reclassification 2026: What Researchers Want Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC Is BPC 157 Banned? Oral vs. Injectable Forms Explained